Hepatitis C Articles (HCV)
Back
	Abbvie (formerly Abbott) HCV Drug Program       Abbvie is currently in a large phase 3 trials program, its expected that by June 2014 Abbvie will submit to the FDA a New drug approval application for this new HCV IFN-free regimen, standard procedure for new drug approvals......   EASL: SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/- RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY - (04/25/13)   IAS: SAFETY OF RIBAVIRIN-CONTAINING REGIMENS OF ABT-450/r, ABT-333, AND ABT-267 FOR THE TREATMENT OF HCV GENOTYPE 1 INFECTION AND EFFICACY IN SUBJECTS WITH RIBAVIRIN DOSE REDUCTIONS - (07/03/13)           View Older Articles   Back to Top   www.natap.org